IMPACT BIOMEDICAL INC.
IBO evidence brief
What we can confirm
- BioSniper Score:
- 6.6 / 10
- Market Cap:
- $49.6M
- Next Catalyst:
- Phase2_Start · Dec 1, 2026
What it means
What to watch
Prepared research question
What matters most for IBO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IBO
IMPACT BIOMEDICAL INC. (IBO) is a development-stage biotechnology company with no reported revenue, operating through subsidiaries such as Global BioLife and Sweet Sense, and advancing a Phase II Parkinson's disease trial for ENERGI-F705 tablets.
Key risk: No revenue, net loss
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 6 clinical trials · 1 catalyst for IMPACT BIOMEDICAL INC..
IMPACT BIOMEDICAL INC. (IBO) is a development-stage biotechnology company with no reported revenue, operating through subsidiaries such as Global BioLife and Sweet Sense, and advancing a Phase II Parkinson's disease trial for ENERGI-F705 tablets.
- As of 2026-06-30, the company reported $0.0M in total revenue and a net loss of -$0.7M [sec].
- Shareholders' equity stood at $10.8M as of 2026-06-30 [sec].
- The company's business model includes partnering and potential direct sales, with revenue from milestone and royalty payments [sec_mda · as of 2026-05-12].
- Operations are conducted through subsidiaries including Global BioLife, Impact BioLife, Global BioMedical, and Sweet Sense [sec_mda · as of 2026-05-12].
- A Phase II, randomized, double-blind, placebo-controlled study of ENERGI-F705 tablets for Parkinson's disease is scheduled to start on 2026-12-01 [catalyst].
What works
- The company has a structured business model that includes partnering with pharmaceutical and consumer packaged goods companies, which can reduce internal commercialization costs [sec_mda · as of 2026-05-12].
- A Phase II clinical trial for ENERGI-F705 in Parkinson's disease is planned, indicating progression beyond early-stage development [catalyst].
What to weigh
- The company has no reported revenue and a net loss of -$0.7M as of 2026-06-30, reflecting a pre-revenue development stage [sec].
- Shareholders' equity of $10.8M as of 2026-06-30 is relatively modest, which may limit the ability to fund multiple late-stage trials simultaneously [sec].
- The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations [sec_mda · as of 2026-08-07].
From the filings
Quoted directly from source documents.
Business model relies on partnerships and milestone payments.
“Our business model includes partnering and potentially direct sales for commercialization and distribution. Potential licensors and development partners include pharmaceutical, consumer packaged goods companies and others, who would commercialize IBO technologies in exchange for milestone, and royalty payments.”
SEC MD&A · May 12, 2026
Catalyst timeline
- 2026-12-01 · Phase2_Start — A Phase II, randomized, double-blind, placebo-controlled study of ENERGI-F705 tablets for Parkinson's disease is scheduled to begin.
Risks & what to watch (3)›
Key risks
- No revenue, net loss — Zero revenue and a net loss of -$0.7M as of 2026-06-30 indicate no commercial product sales [sec].
- Modest equity base — Shareholders' equity of $10.8M as of 2026-06-30 may constrain funding for multiple late-stage trials [sec].
- Forward-looking statement risks — Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially [sec_mda · as of 2026-08-07].
What to watch
- Initiation and enrollment of the Phase II ENERGI-F705 Parkinson's disease trial starting 2026-12-01 [catalyst].
- Any updates on partnering agreements or milestone payments that could generate first revenue [sec_mda · as of 2026-05-12].
- Changes in cash position or equity in future financial filings, as the company is pre-revenue [sec].
Sources: Catalysts · Competitor trials · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run IMPACT BIOMEDICAL INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available IMPACT BIOMEDICAL INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.25
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~48d
No insider transactions in the last 180 days
Catalysts
Regulatory
Financials
Short Interest
as of Apr 21, 2026- % of float
- 16.3%
- Days to cover
- 0.2
- Shares short
- 1,915,023
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IBO short interestGovernance
Frequently asked questions
What is the AI investment thesis for IMPACT BIOMEDICAL INC.?
IMPACT BIOMEDICAL INC. (IBO) is a development-stage biotechnology company with no reported revenue, operating through subsidiaries such as Global BioLife and Sweet Sense, and advancing a Phase II Parkinson's disease trial for ENERGI-F705 tablets.
What is IMPACT BIOMEDICAL INC.'s next catalyst?
IMPACT BIOMEDICAL INC.'s next tracked catalyst is a Phase2_Start event — "Phase2_Start: A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets in Combination With Standard of Care for Treating Subjects With Parkinson's Disease" — expected December 1, 2026.
Who is the CEO of IMPACT BIOMEDICAL INC.?
Mr. Frank D. Heuszel Esq., J.D. is the chief executive officer of IMPACT BIOMEDICAL INC. (IBO).
Where is IMPACT BIOMEDICAL INC. headquartered?
IMPACT BIOMEDICAL INC. (IBO) is headquartered in Houston, TX, United States.
What therapeutic areas does IMPACT BIOMEDICAL INC. focus on?
IMPACT BIOMEDICAL INC. develops therapies across Oncology, Neurology, Immunology, Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.